Immunotherapy Archives

News and Trends 31 Jan 2023

The next breakthrough in cancer treatment?

In our body, we have an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK (natural killer) cells. This is a type of immune cell that specializes in killing cancer cells. These cells may be of great importance for cancer treatment in […]

January 31, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type I Interferon signaling on tumor-killing CD8+ T cells. The findings provided new insights into the development of exhausted CD8+ T cells, which no longer effectively […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Brenus Pharma and InSphero AG have received a €1.5 million grant for the collaborative project “STC-1010: A First-in-Class Allogeneic Cell Vaccine Against Cancer,” which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer. Funding was provided by the Eurostars fund, a support mechanism for small and medium-sized enterprises under […]

January 20, 2023 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

December 20, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2022

Watch: Valo Therapeutics at Bio-Europe

Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 20 Dec 2022

Watch: Mendus interview

Mendus AB is a Swedish company dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. The company leverages its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy […]

December 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

ImaginAb launches trial to study neoadjuvant immunotherapy

ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety of neoadjuvant immune checkpoint inhibitor treatment of stage III surgically resectable melanoma through use of CD8 ImmunoPET. ImaginAb is a global biotechnology company focused on […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Etcembly reveals breakthrough in optimizing TCR assets

Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

December 9, 2022

News and Trends 7 Dec 2022

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

The next breakthrough in cancer treatment?

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Watch: Valo Therapeutics at Bio-Europe

Watch: Mendus interview

Sanofi and Innate Pharma expand natural killer cell deal

ImaginAb launches trial to study neoadjuvant immunotherapy

Etcembly reveals breakthrough in optimizing TCR assets

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!